Skip to content
  • HOME
  • UPDATES
  • WHAT IS IT?
  • WHY?
    • Formulation of hydrophobic compounds
  • Q&A
  • RESEARCHERS
  • ABOUT US
  • CONTACT
  • HOME
  • UPDATES
  • WHAT IS IT?
  • WHY?
    • Formulation of hydrophobic compounds
  • Q&A
  • RESEARCHERS
  • ABOUT US
  • CONTACT

Protected: Losartan-N: animal study

  • by novochizol
  • March 26, 2020September 17, 2020

This content is password protected. To view it please enter your password below:

Tags:animal studieshypertensionlosartansartans

Subscribe to our news

UPDATES

  • test December 17, 2020
  • GlobalData CRO invitation June 8, 2020
  • Eight drug/drug candidates formulated as aerosols June 6, 2020
  • Making hydrophobic compounds “soluble” with customizable release properties June 6, 2020
  • Inhaled Losartan in COVID-19 – Interview April 15, 2020
  • Digoxin-N preclinical dose escalation April 13, 2020
  • Angiotensin Receptor Blockers: Pros and Cons April 4, 2020
  • Pharmacokinetics questions March 28, 2020
  • PRESS RELEASE March 26, 2020
  • Why Losartan? March 26, 2020
  • Losartan-N in 48 hours March 26, 2020
  • Protected: Losartan-N: animal study March 26, 2020
  • Why Digoxin? March 26, 2020
  • What other drugs? March 26, 2020

Neve | Novochizol is Trade Mark of Bosti Trading LTD.